Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurène Fenwarth

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
BMC Palliative Care|January 31, 2025
Cross-referencing French hematology teams' knowledge and perception of end-of-life situations: a national mixed-methods surveyChloé Prod'homme, Côme Bommier, Laurène Fenwarth, et al.
Expert Opinion on Therapeutic Targets|April 28, 2021
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implicationsFanny Gonzales, Adeline Barthélémy, Pauline Peyrouze, et al.
Bulletin Du Cancer|October 28, 2022
[Management of genetic predisposition to hematologic malignancies in patients undergoing allogeneic hematopoietic cell transplantation (HCT): Guidelines from the SFGM-TC]Valérie Coiteux, Laurène Fenwarth, Nicolas Duployez, et al.
BMJ Supportive & Palliative Care|March 27, 2020
Clinical research in cancer palliative care: a metaresearch analysisMarie Vinches, Anouk Neven, Laurène Fenwarth, et al.
International Journal of Molecular Sciences|August 13, 2020
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentLaurène Fenwarth, Elise Fournier, Meyling Cheok, et al.
Cancer Medicine|March 20, 2024
Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic eraAlexandre Iat, Michael Loschi, Sami Benachour, et al.
British Journal of Haematology|December 19, 2025
Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot studyAugustin Boudry, Florian Chevillon, Alice Marceau-Renaut, et al.
BMC Bioinformatics|October 28, 2022
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3rAugustin Boudry, Sasha Darmon, Nicolas Duployez, et al.
British Journal of Haematology|September 3, 2025
Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemiaAugustin Boudry, Laure Goursaud, Delphine Lebon, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
BMC Palliative Care|January 31, 2025
Cross-referencing French hematology teams' knowledge and perception of end-of-life situations: a national mixed-methods surveyChloé Prod'homme, Côme Bommier, Laurène Fenwarth, et al.
Expert Opinion on Therapeutic Targets|April 28, 2021
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implicationsFanny Gonzales, Adeline Barthélémy, Pauline Peyrouze, et al.
Bulletin Du Cancer|October 28, 2022
[Management of genetic predisposition to hematologic malignancies in patients undergoing allogeneic hematopoietic cell transplantation (HCT): Guidelines from the SFGM-TC]Valérie Coiteux, Laurène Fenwarth, Nicolas Duployez, et al.
BMJ Supportive & Palliative Care|March 27, 2020
Clinical research in cancer palliative care: a metaresearch analysisMarie Vinches, Anouk Neven, Laurène Fenwarth, et al.
International Journal of Molecular Sciences|August 13, 2020
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentLaurène Fenwarth, Elise Fournier, Meyling Cheok, et al.
Cancer Medicine|March 20, 2024
Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic eraAlexandre Iat, Michael Loschi, Sami Benachour, et al.
British Journal of Haematology|December 19, 2025
Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot studyAugustin Boudry, Florian Chevillon, Alice Marceau-Renaut, et al.
BMC Bioinformatics|October 28, 2022
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3rAugustin Boudry, Sasha Darmon, Nicolas Duployez, et al.
British Journal of Haematology|September 3, 2025
Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemiaAugustin Boudry, Laure Goursaud, Delphine Lebon, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Pageof 3